Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005 – 2011

BMC Infectious Diseases

Joshua T Freeman¹  Sally A Roberts¹  Siouxsie Wiles²  Alwin Lim²  Deborah A Williamson³ 

[1] Department of Clinical Microbiology, Auckland District Health Board, Park Road, Auckland, Grafton, New Zealand;Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand;Institute of Environmental Science and Research, Wellington, New Zealand

关键词: Antimicrobial resistance;    Bacteremia;    Escherichia coli;   

Others  :  1146067
DOI  :  10.1186/1471-2334-13-385

 received in 2013-04-22, accepted in 2013-08-08,  发布年份 2013

【 摘 要 】

Background

Escherichia coli is a major human pathogen, both in community and healthcare settings. To date however, relatively few studies have defined the population burden of E. coli bloodstream infections. Such information is important in informing strategies around treatment and prevention of these serious infections. Against this background, we performed a retrospective, population-based observational study of all cases of E. coli bacteremia in patients presenting to our hospital between January 2005 and December 2011.

Methods

Auckland District Health Board is a tertiary-level, university-affiliated institution serving a population of approximately 500,000, within a larger metropolitan population of 1.4 million. We identified all patients with an episode of bloodstream infection due to E. coli over the study period. A unique episode was defined as the first positive E. coli blood culture taken from the same patient within a thirty-day period. Standard definitions were used to classify episodes into community- or healthcare-associated E. coli bacteremia. Demographic information was obtained for all patients, including: age; gender; ethnicity; length of stay (days); requirement for intensive care admission and all-cause, in-patient mortality.

Results

A total of 1507 patients had a unique episode of E. coli bacteremia over the study period. The overall average annual incidence of E. coli bacteremia was 52 per 100,000 population, and was highest in the under one year and over 65-year age groups. When stratified by ethnicity, rates were highest in Pacific Peoples and Māori (83 and 62 per 100,000 population respectively). The incidence of community-onset E. coli bacteremia increased significantly over the study period. The overall in-hospital mortality rate was 9% (135/1507), and was significantly higher in patients who had a hospital-onset E. coli bacteremia.

Conclusions

Our work provides valuable baseline data on the incidence of E. coli bacteremia in our locale. The incidence was higher that that described from other developed countries, with significant demographic variation, most notably in ethnic-specific incidence rates. Future work should assess the possible reasons for this disparity.

【 授权许可】

   
2013 Williamson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Russo TA, Johnson JR: Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 2003, 5(5):449-456.
• [2]Hounsom L, Grayson K, Melzer M: Mortality and associated risk factors in consecutive patients admitted to a UK NHS trust with community acquired bacteremia. Postgrad Med J 2011, 87(1033):757-762.
• [3]Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL: Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis 2005, 191(9):1523-1529.
• [4]Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FR 3rd, St Sauver JL, Wilson WR, Baddour LM: Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch Intern Med 2007, 167(8):834-839.
• [5]Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD: Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008, 14(11):1041-1047.
• [6]Laupland KB, Kibsey PC, Gregson DB, Galbraith JC: Population-based laboratory assessment of the burden of community-onset bloodstream infection in Victoria. Canada. Epidemiol Infect 2013, 141(1):174-180.
• [7]Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gur D, Jarlier V, Kahlmeter G, Monen J, Monnet DL, Rossolini GM, Suetens C, Weist K, Heuer O, EARS-Net Participants (Disease Specific Contact Points for AMR): Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011, 16(11):19819.
• [8]Schlackow I, Stoesser N, Walker AS, Crook DW, Peto TE, Wyllie DH, Infections in Oxfordshire Research Database Team: Increasing incidence of Escherichia coli bacteremia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999–2011. J Antimicrob Chemother 2012, 67(6):1514-1524.
• [9]Melzer M, Welch C: Is Escherichia coli bacteremia preventable? Lancet Infect Dis 2012, 12(2):103-104.
• [10]Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, Pascale DG, Proli EM, Cauda R, Cicchetti A, Fadda G: Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010, 54(10):4085-4091.
• [11]Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T: Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51(6):1987-1994.
• [12]Kennedy KJ, Roberts JL, Collignon PJ: Escherichia coli bacteremia in Canberra: incidence and clinical features. Med J Aust 2008, 188(4):209-213.
• [13]Tong SY, Van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD: Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in indigenous Australians. BMC Infect Dis 2012, 12(1):249. BioMed Central Full Text
• [14]Flory JH, Joffe M, Fishman NO, Edelstein PH, Metlay JP: Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 2009, 137(5):717-726.
• [15]Statistics New Zealand: 2006 census of populations and dwellings. District Health Board Area summary tables. (http://www.stats.govt.nz/Census/about-2006-census/district-health-board-area-summary-tables.aspx webcite). Last accessed July 30th, 2013
• [16]World Health Organization: International statistical classification of diseases and related health problems. 10th edition. 2010.
• [17]Williamson DA, Roberts SA, Ritchie SR, Coombs GW, Fraser JR, Heffernan H: Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus in New Zealand: rapid emergence of Sequence Type 5 (ST5)-SCCmec-IV as the dominant community-associated MRSA clone. PLoS One 2013, 8(4):E62020.
• [18]Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; 22nd Informational Supplement M100-S22. PA, USA: CLSI, Wayne; 2012.
• [19]Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281.
• [20]Skogberg K, Lyytikainen O, Ollgren J, Nuorti JP, Ruutu P: Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect 2012, 18(6):E170-6.
• [21]Williamson DA, Ritchie SR, Lennon D, Roberts SA, Stewart J, Thomas MG, Baker MG: Increasing incidence and sociodemographic variation in community-onset Staphylococcus aureus skin and soft tissue infections in New Zealand children. Paed Infect Dis J 2013, 32(8):923-925.
• [22]Baker MG, Sneyd E, Wilson NA: Is the major increase in notified campylobacteriosis in New Zealand real? Epidemiol Infect 2007, 135(1):163-170.
• [23]Arnold R, Galloway Y, McNicholas A, O’Hallahan J: Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011, 29(40):7100-7106.
• [24]Olesen B, Kolmos HJ, Orskov F, Orskov I, Gottschau A: Bacteremia due to Escherichia coli in a Danish university hospital, 1986–1990. Scand J Infect Dis 1995, 27(3):253-257.
• [25]Baker MG, Barnard LT, Kvalsvig A, Verrall A, Zhang J, Keall M, Wilson N, Wall T, Howden-Chapman P: Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet 2012, 379(9821):1112-1119.
• [26]Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, Murdoch D, Pottumarthy S, Roberts SA, Swager C, Taylor SL, Thomas MG, Wong CG, Morris AJ: Prospective study of 424 cases of Staphylococcus aureus bacteremia: determination of factors affecting incidence and mortality. Intern Med J 2001, 31(2):97-103.
• [27]Ritchie SR, Fraser JD, Libby E, Morris AJ, Rainey PB, Thomas MG: Demographic variation in community-based MRSA skin and soft tissue infection in Auckland. New Zealand. N Z Med J 2011, 124(1332):21-30.
• [28]Tukuitonga CR, Bell S, Robinson E: Hospial admission among Pacific children Auckland 1992–97. N Z Med J 2000, 113(1116):358-361.
• [29]Malcolm L: Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders. N Z Med J 1996, 109(1030):356-358.
• [30]Smith J, Jackson G, Orr-Walker B, Jackson R, Sinclair S, Thornley S, Riddell T, Chan WC: A population-based approach to the estimation of diabetes prevalence and health resource utilisation. N Z Med J 2010, 123(1310):62-73.
• [31]Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB: The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012, 12(85):2334.
• [32]Cheong HS, Kang CI, Kwon KT, Heo ST, Wi YM, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY, Song JH, Peck KR: Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteremia. J Antimicrob Chemother 2007, 60(6):1355-1360.
• [33]Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, Lee NY, Song JH: Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol 2012, 50(2):312-317.
• [34]Williamson DA, Sidjabat HE, Freeman JT, Roberts SA, Silvey A, Woodhouse R, Mowat E, Dyet K, Paterson DL, Blackmore T, Burns A, Heffernan H: Identification and molecular characterisation of New Delhi metallo-beta-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents 2012, 39(6):529-533.
• [35]Williamson DA, Heffernan H, Sidjabat H, Roberts SA, Paterson DL, Smith M, Freeman JT: Intercontinental transfer of OXA-181-producing Klebsiella pneumoniae into New Zealand. J Antimicrob Chemother 2011, 66(12):2888-2890.
• [36]Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT: Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012, 54(10):1406-1412.